Actively Recruiting
Mpox Comprehensive Assessment for Responsive Immunisation in Emergency Outbreaks
Led by University of Birmingham · Updated on 2025-03-20
650
Participants Needed
1
Research Sites
N/A
Total Duration
On this page
Sponsors
U
University of Birmingham
Lead Sponsor
R
Rwanda Biomedical Centre
Collaborating Sponsor
AI-Summary
What this Trial Is About
Researchers are investigating Mpox, a disease with rising cases in Central and East Africa, caused by two virus strains with different characteristics and spread patterns. The study aims to develop new immune tests to estimate how many people have been exposed to Mpox or vaccinated, helping to prioritize vaccine use in affected communities. This outbreak is considered a public health emergency due to increasing cases and deaths, especially with limited testing in some regions. Participants are grouped by their exposure status: those at risk but without symptoms, those recovered from Mpox or vaccinated, and those with no known exposure. The study uses diagnostic tests including an Mpox-specific antibody ELISA and a dried blood spot lateral flow assay to detect immune responses. All participants undergo the same testing procedures to assess their exposure or immunity status. During the study visit, participants provide biological samples for testing and complete surveys about their views on outbreak studies, immune diagnostic tools, and vaccine logistics. Researchers will measure Mpox-specific antibodies and evaluate rapid test accuracy. The study will also gather perspectives from healthcare workers and the public to support future vaccine strategies. The total participation involves sampling and questionnaires conducted on the first day.
CONDITIONS
Brief Title
Mpox Comprehensive Assessment for Responsive Immunisation in Emergency Outbreaks
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Healthy males and females aged between 5 and 80 years who can provide informed consent and follow study requirements
- For suspected exposure group: live within or near a Mpox transmission area or be a close contact of confirmed Mpox cases
- For post-exposure/vaccinated group: previous confirmed Mpox infection or vaccination and fully recovered
- For control group: asymptomatic with no known Mpox exposure
You will not qualify if you...
- Unable or unwilling to provide informed consent or comply with study procedures
- History of immune system disorders that might affect study results
- Significant bleeding disorders
- Pregnant or breast-feeding females
- Suspected exposure group: known Mpox infection, current Mpox symptoms, or recent exposure within one month
- Post-exposure/vaccinated group: ongoing Mpox symptoms
- Control group: Mpox symptoms or recent exposure within one month
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Your Study Journey
Duration - 2 to 4 weeks
Participants are screened for eligibility to participate in the trial.
1 visit (in-person)
Duration - 1 day
Participants undergo diagnostic tests to detect Mpox exposure through antibody assays.
1 visit (in-person)
Trial Site Locations
Total: 1 location
1
Rwanda Biomedical Center
Kigali, Rwanda, P.O. Box 7162
Actively Recruiting
Research Team
S
Shema Hugor
K
Karishma Gokani
How is the study designed?
Study Type
INTERVENTIONAL
Masking
NONE
Allocation
NA
Model
SINGLE_GROUP
Primary Purpose
DIAGNOSTIC
Number of Arms
1
Similar Trials
Frequently Asked Questions
Have more questions? Get in touch with our team for quick support
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here